Can a Drug-Vaccine combo delay leukemia in High-Risk patients?
NCT ID NCT02518555
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested whether giving the targeted drug ibrutinib along with standard vaccines (pneumonia, flu, and Tdap) can help people with early-stage, high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) stay progression-free longer. The study enrolled 42 asymptomatic patients with high-risk genetic features. The goal was to see if early intervention could delay the need for stronger treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ibrutinib (a targeted cancer drug) and vaccines (pneumococcal, influenza, and Tdap)
- What this could lead to
- If successful, this could show that early use of ibrutinib with vaccines delays disease progression in high-risk CLL/SLL patients who are not yet sick.
- What could go wrong
- This is a small, early-phase trial (42 participants) with no control group for comparison. Ibrutinib has side effects like bleeding and infection risk, and the vaccines may not boost immunity as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Smartwatches track hidden heart risk in blood cancer patients
- New biologic MK-1045 targets Hard-to-Treat blood cancers
- Triple-drug attack aims to wipe out hidden leukemia cells
- New transplant recipe aims to tame Graft-Versus-Host disease
- Engineered immune cells take aim at stubborn blood cancers